Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
MeiraGTx Holdings plc logo

NASDAQ · MGTX

MeiraGTx Holdings plc

Healthcare · Biotechnology

$12.76

Up+$0.00 (+0.00%)

Updated Sep 17, 2026, 3:03 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
701.08M
P/E ratio
-4.18
Dividend yield
0.00%
52-week range
$6.62 – $15.35
Volume
917.36K
Avg. volume
497.35K

Price performance

MGTX price history

1M range · 20 trading sessions · Daily adjusted prices

MGTX closed at $12.76 after 20 trading sessions, down 14.76% for the selected period.

Last close
$12.76
Period change
-14.76%
Period low
$12.76
Period high
$14.97
Daily close
View OHLC price history
MGTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$12.79$12.95$12.63$12.76917.36K
Sep 15, 2026$12.88$12.885$12.50$12.761.03M
Sep 14, 2026$12.81$13.22$12.76$12.88492.32K
Sep 11, 2026$13.04$13.14$12.75$12.79459.55K
Sep 10, 2026$13.02$13.16$12.645$12.85716.51K
Sep 9, 2026$13.40$13.76$13.245$13.26534.37K
Sep 8, 2026$13.539$13.72$13.2174$13.53611.45K
Sep 4, 2026$13.70$14.045$13.60$13.89531.15K
Sep 3, 2026$14.01$14.15$13.76$13.97824.11K
Sep 2, 2026$14.48$14.73$13.7216$14.06629.37K
Sep 1, 2026$13.66$14.60$13.66$14.19880.48K
Aug 31, 2026$13.895$14.14$13.3901$13.81715.73K
Aug 28, 2026$13.93$14.09$13.65$13.82914.21K
Aug 27, 2026$14.46$14.575$14.116$14.141.01M
Aug 26, 2026$14.85$14.92$14.41$14.56606.49K
Aug 25, 2026$15.01$15.31$14.6323$14.92689.61K
Aug 24, 2026$14.28$14.94$13.72$14.83821.37K
Aug 21, 2026$14.70$14.845$14.10$14.34635.48K
Aug 20, 2026$14.93$15.01$14.495$14.54861.87K
Aug 19, 2026$14.29$15.05$14.08$14.971.1M

Latest MGTX news

The latest Smart Investors Daily articles mentioning MGTX.

Stock researchCompany · Overview

MGTX research

Overview

Company profile and research snapshot.

Company profile

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
MGTX recent ratings
DateFirmRatingTarget
Aug 14, 2026RBC CapitalOutperform—
Jul 8, 2026RBC CapitalOutperform—
Jul 8, 2026HC Wainwright & Co.Buy—
May 15, 2026RBC CapitalOutperform—
Apr 22, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a multicenter Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerability, and efficacy of GV101 in patients with moderate to severe chronic Graft versus Host Disease (cGvHD). The data, published in Signal Transduction and Targeted Therapy, a Springer Nature Portfolio journal, provide efficacy and findings from the 60 enrolled pat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By